Skyrizi Growth Deceleration Could Test AbbVie Stock
AbbVie (ABBV) is experiencing a slight slowdown in Skyrizi's growth rate, which could impact investor confidence. While the drug still grew by 29.2% year-over-year to $4.5 billion in sales, it marked a deceleration from its previous quarter’s 31.9%. As AbbVie relies heavily on Skyrizi and Rinvoq for post-Humira growth, any sustained slowdown could challenge the company's ability to meet top-tier performance expectations.
Tickers: $ABBV $BMY $JNJ $MRK $PFE